Jefferson Journal of Psychiatry
Volume 20

Issue 1

Article 11

December 2006

Download the PDF of the Full Issue

Follow this and additional works at: https://jdc.jefferson.edu/jeffjpsychiatry
Part of the Psychiatry Commons

Let us know how access to this document benefits you
Recommended Citation
(2006) "Download the PDF of the Full Issue," Jefferson Journal of Psychiatry: Vol. 20 : Iss. 1 , Article 11.
DOI: https://doi.org/10.29046/JJP.020.1
Available at: https://jdc.jefferson.edu/jeffjpsychiatry/vol20/iss1/11

This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital
Commons is a service of Thomas Jefferson University's Center for Teaching and Learning (CTL). The Commons is
a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections
from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested
readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been
accepted for inclusion in Jefferson Journal of Psychiatry by an authorized administrator of the Jefferson Digital
Commons. For more information, please contact: JeffersonDigitalCommons@jefferson.edu.

THE
JEFFERSON
JOURNAL
OF
PSYCHIATRY

A Resident Publication
Volume Twenty, Number One 2006

ISSN 1935-0783

Table of Contents
Articles
What Investigations Are Ordered in Patients with First-episode
Psychosis?
Allan Shefrin, M.D. (PGY2), Derek Puddester, M.D., Stephanie
Greenham, Ph.D., Lise Bisnaire, Ph.D., Hazen Gandy, M.D.

4

Psychogenic Stuttering Following a Gastric Bypass Operation:
Case Report
Deborah B. Raphael, M.D. (PGY2), Frank B. Schoenfeld, M.D.

13

Psychiatric Diagnoses in Patients with Williams Syndrome and
Their Families
Janet C. Kennedy, M.D. (PGY1), David L. Kaye, M.D., Laurie S.
Sadler, M.D.

22

No More Cuts: The Curious Fate of Self-Mutilation in Its
Development
Zhabiz Kazeminezhad, M.D. (PGY4), Salman Akhtar, M.D.

32

First-Known Hypnopompic Hallucination Occurring In-Hospital:
Case Report
Paul Ballas, D.O. (PGY2)

38

Special Essays and Responses
A Kind of Poem for My Friend and Me
Hilary O’Neill, M.D. (PGY4)

43

Mourning
Salman Akhtar, M.D.

46

Jefferson Journal of Psychiatry, Volume 20, Number 1
© 2006 by the authors
On the Web: jdc.jefferson.edu/jeffjpsychiatry

ISSN 1935-0783

2

Updates and Reviews
Neuroleptic Malignant Syndrome, with Attention to Its Occurrence
with Atypical Antipsychotic Medication: A Review
Sarah Guzofski, M.D. (PGY2), Ruben Peralta, M.D.

53

Editorials
NMS, and Why We Should Call It (Malignant) Catatonia
Robert Arnold Johnson, M.D. (PGY4)

62

Editorial Board

69

Jefferson Journal of Psychiatry, Volume 20, Number 1
© 2006 by the authors
On the Web: jdc.jefferson.edu/jeffjpsychiatry

ISSN 1935-0783

3

What Investigations Are Ordered in Patients
with First-episode Psychosis?
Allan Shefrin, M.D. (PGY2), Derek Puddester, M.D., Stephanie Greenham, Ph.D.,
Lise Bisnaire, Ph.D., Hazen Gandy, M.D.

ABSTRACT
Psychiatrists are often left with the dilemma of which investigations to order
in adolescents presenting with a first episode of psychosis. Blood work, urine
studies, and neuroimaging studies were tracked in 13 adolescents admitted
with a diagnosis of first-episode psychosis over a 13-month period to the
Children’s Hospital of Eastern Ontario. Variation was found in the amount of
investigation ordered: 85% of patients received a drug screen; 54% a CT
scan; 8% an MRI; 92% a CBC with differential; 92% electrolytes.
Abnormalities of CT scans were detected in 2 patients (29%); in neither case
did the result lead to a diagnosis of brain-lesion-related psychosis, nor did it
affect the clinical care of the patient. This study highlights the need to develop
clinical practice-guidelines for the workup of first-episode psychosis in
adolescents.
First-episode psychosis has received considerable attention in both the pediatric
and adult literature. One area of ongoing research is the degree to which children
and adolescents require investigations to rule in or rule out non-psychiatric disease.
According to the Diagnostic and Statistical Manual of Mental Disorders 4th Edition
Text Revision (DSM-IV-TR), the diagnosis of schizophrenia and other psychotic
illnesses require that criteria be met: where “the disturbance is not due to the direct
physiological effects of a substance (e.g., of abuse or a medication) or a general
medical condition”(1). Yet, in spite of these essential criteria, a standardized workup for first episode psychosis in children and youth is difficult to find.
Psychiatry associations and textbooks differ in their recommendations and often
leave the decision to perform a test at the discretion of the attending physician. A
summary of different guidelines can be found in Table 1.
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Table 1: Summary of various guidelines for the investigation of patients with first episode psychosis
Suggested Work-up
Source
Kaplan and Sadock(2)
• Do: complete history and physical exam, urine toxicology screen,
CBC, general chemistry screen, urinalysis
• Consider: pregnancy test, ECG, MRI, CT, EEG
Rutter and Taylor(3)
• Do: CBC, ESR, electrolytes, renal function tests, glucose, calcium,
magnesium, phosphate, liver enzymes, albumin, TSH, urinalysis, urine
toxicology screen
• Consider: neuroimaging
Wiener(4)
• Do: sexually transmitted disease screen
• Consider other investigations as guided by history and physical exam
American Psychiatric
• Do: history and physical exam, thyroid function tests, renal function
Association(5)
tests, liver function tests, pregnancy screen, toxicology screen, syphilis
screen
• Consider: screening for HIV and hepatitis C, EEG/CT/MRI if indicated
(new onset psychosis and atypical psychosis)
American Association of
• Consider: CBC, chemistry, thyroid function tests, urinalysis, toxicology
Child and Adolescent
screen, infectious disease screens (if at risk)+, chromosomal analysis (if
Psychiatrists (AACAP)(6, 7)
suggestive of developmental syndrome), neuroimaging (if evidence of
neurologic dysfunction)
CBC – complete blood count / ECG – electrocardiogram
MRI – magnetic resonance imaging / CT – computed Tomography
EEG – electroencephalogram / ESR – erythrocyte sedimentation rate
TSH – thyroid stimulating hormone
+
- high risk groups include: all adolescents with psychiatric symptoms; high risk adolescents (e.g.: runaways,
delinquents, children of substance abusers); adolescents with changes in mental status or performance; adolescents
with acute behavior changes; adolescents with recurrent accidents or unexplained somatic symptoms; adolescents
for whom abstinence is to be monitored

There is much debate in the literature regarding the inclusion of neuroimaging in
the standard work-up of children with first-episode psychosis. Some advocate a
rule-in approach while others prefer a rule-out approach. The AACAP suggests
that the use of CT and MRI be reserved for ruling out intracranial disease when
suspected, and that they are of very low positive yield in the absence of clinical
findings.(6, 7) Adams et al. conclude that routine endocrine and neuroimaging
screening tests in first-onset adolescent psychosis are of little diagnostic utility and
are not cost effective (8). They recommend that investigations be reserved for
cases with symptoms suggestive of non-psychiatric pathology. Larson et al.
concluded that CT scans should be used to rule in intracranial pathology as it has
low yield in assisting clinical decisions in the absence of focal neurologic deficit
(9).
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Yet a growing body of evidence suggests the potential value of neuroimaging for
patients with first-episode psychosis. Various CT studies in adolescents and adults
have found that patients with schizophrenia and other psychotic disorders exhibit
ventricular enlargement, cortical atrophy, and cerebrospinal-fluid (CSF)
circulation-disturbances (10-16). Magnetic resonance imaging is increasingly
being used as a diagnostic and research tool in psychiatric illness. Various studies
report gray matter deficits, increased CSF volume, decreased cerebral volume,
thalamic abnormalities, and diminished size of the fusiform gyrus associated with
psychosis (15-22). Jacobsen and Rapoport suggest that CT and MRI changes are
not static but are affected by the duration or severity of illness and the modality
and success of treatment (21).
Moreno et al. note that the interpretation of pediatric neuroimaging studies is
difficult, owing to the variability of normal results secondary to age and body-size.
They also note that diagnostic testing may be required in assisting patients and
their families in gaining access to social and financial services (23).
Finally, many psychiatrists have informally reported cases of first-episode
psychosis that have later been determined to result from a general medical
condition (for example, intracranial tumor, developmental structural anomalies,
metabolic disease, genetic disease, or seizure disorder). Thus, some psychiatrists
advocate that a thorough workup should be done from a quality and risk
management perspective. But few data, to date, support this perspective.

METHODS
All psychiatry inpatients admitted for the 13 months from October 1, 2000 to
October 31, 2001 were eligible for entry into the study database. Patients or their
legal guardians (for those under 16 years of age) gave consent for their inclusion.
The Research Ethics Board of the Children’s Hospital of Eastern Ontario (CHEO)
approved the study.
Patients were excluded from this study if they had a seizure disorder, diabetes,
anemia, migraine, endocrine disorder, or vitamin B12 deficiency. Patients
readmitted to service were also excluded.
This process identified 174 patients, of which 13 presented with a primary
diagnosis of psychosis. The remainder had mood or anxiety disorders. There were
many more cases of psychosis, but they either presented with mood symptoms, or
the psychosis was not evident at the time of admission. The 13 diagnosed with
first-episode psychosis were age 14 to 17 years; 9 were male and 4 were female.
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Research assistants reviewed all inpatient charts and records and biological data
was entered into the study database. Laboratory results were collected for patients
and were divided based on whether tests were normal, abnormal, abnormally high,
abnormally low and not ordered. Percentages of normal and abnormal results were
calculated based on the number of tests ordered. With the exception of the CBC
and urinalysis, which are required by the hospital for all admitted patients, tests are
ordered at the discretion of the admitting psychiatrist.

RESULTS
A neuroimaging study was ordered in 62% of patients (Table 2). Of these 8
studies, an abnormality was detected in 2.
Table 2: Results of neuroimaging studies for children and adolescents admitted to the Children’s
Hospital of Eastern Ontario with a diagnosis of first-episode psychosis
Test

Norm

Abnorm

Not Ordered

CT Head

5

2

6

MRI
EEG

1
8

0
0

12
5

With respect to blood tests and urine toxicology, 92% of the patients were
investigated (Tables 3 and 4).
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Table 3: Laboratory investigations performed in 13 patients admitted to the Children’s Hospital
of Eastern Ontario with a diagnosis of first-episode psychosis
Test
WBC
Neutrophils
Hemoglobin
Platelets
TSH
AST
ALT
Sodium
Chloride
Potassium
Calcium
Magnesium
Phosphate
Glucose
Urea
Creatinine

Normal
8
9
10
12
11
7
8
12
12
12
0
5
5
5
8
10

Abnormal high
2
2
1
0
0
0
1
0
0
0
0
0
0
1
0
1

Abnormal low
2
1
1
0
0
0
3
0
0
0
0
0
0
2
2
0

Not Ordered
1
1
1
1
2
6
1
1
1
1
13
8
8
5
3
2

Table 4: Toxin and drug of abuse testing in a sample of children and adolescents admitted to the
Children’s Hospital of Eastern Ontario with a diagnosis of first-episode psychosis
Toxin Screened

Negative Positive

Not ordered

Acetaminophen
Salicylates
Ethanol
Phencyclidine
Benzodiazepines
Cocaine
Amphetamines
Tetrahydrocannabinol
Opiates
Barbiturates

0
0
1
11
8
11
10
7
10
11

11
11
12
2
2
2
2
2
2
2

2
2
0
0
3
0
1
4
1
0

No patients were tested for sexually transmitted diseases. Two of the four female
patients were tested for pregnancy. Both tests were negative.
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DISCUSSION
There is considerable variation in investigations ordered by admitting
psychiatrists for the workup of first-episode psychosis. Psychiatrists, overall, at the
Children’s Hospital of Eastern Ontario tended to order more tests than are
recommended by some authors, but vary greatly among themselves: 85% of
patients received a drug screen, 54% received a CT scan, 8% received an MRI and
92% received a CBC with differential and electrolytes. The variability may result
from the lack of a clear practice guideline from an authoritative source or the risks,
both medical and legal, of missing an alternative diagnosis. Some sources suggest
the variability results from the lack of confidence psychiatrists have in their
medical knowledge (8).
Attention should be given to differentiating which tests should be used for
screening purposes and which tests for diagnostic purposes. In our study, 29% of
patients who received a CT scan of the head had an abnormal result. One patient
had a questionable mass in the right frontal lobe (not confirmed by MRI). The
other abnormal CT was suggestive of slightly large ventricles; MRI investigation
was not done on this patient during the study period. Neither abnormal CT result
impacted on the patient’s diagnosis or treatment. As MRI becomes more accessible
and affordable in Canada and a better understanding of the relationship between
clinical and neuroimaging findings is attained, MRI may prove to be of utility in
the clinical investigation of psychosis. This is also true of newer modalities such as
positron emission tomography and single photon emission tomography.
It is widely understood that substance use is common in individuals with
psychosis. Our study found that a considerable percentage of our subjects had
clinically detectable levels of substances in their bodies. Of greater concern,
however, is that 15% of patients were not screened for any substances at all, and
92% were not screened for ethanol. Given that substances can cause psychosis,
affect its prognosis, and represent a major comorbidity, it seems essential that these
particular investigations be considered in all patients with a psychotic presentation.
Limitations of this study are clear. Our sample size is small, and correlative and
causative conclusions cannot be drawn. We did not capture why certain studies
were ordered in some patients and not others. Finally, the study was limited to
biological investigations, and does not include the potentially valuable contribution
of psychological and other evaluations.
Based on the results of this study, we can conclude that there is large variability
in the ordering of investigations at CHEO for adolescents with first-episode
psychosis. The findings of abnormal CT scans correlate with previous studies.
Correlative and causative conclusions cannot be drawn with such a small sample
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size. Therefore, more studies are needed to better standardize admission
investigations and determine clinical correlations with laboratory findings. This
will help guide further investigations such as cost/benefit analysis and monitoring
of disease and treatment response.
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Psychogenic Stuttering Following a Gastric
Bypass Operation: Case Report
Deborah B. Raphael, M.D. (PGY2), Frank B. Schoenfeld, M.D.

ABSTRACT
We evaluated a 44-year-old female with bipolar affective disorder who
presented with a 4-month history of severe stuttering and vague neurologic
complaints. She had lost 200 pounds after gastric bypass surgery two years
before. A childhood sexual- abuse victim, she admits that she “hid” in her
weight for most of her life. Neurological evaluation of this patient was
negative, and speech-pathology evaluation revealed highly atypical stuttering.
Gastric bypass patients with a history of psychiatric disorders and childhood
sexual abuse may be particularly vulnerable to somatoform disorders.
It has been widely reported that psychological complications are prevalent
among the morbidly obese, although this point has been controversial (1). Glinski
et al. elucidated that 70% of patients evaluated for gastric bypass surgery meet
criteria for an Axis I disorder in the past or present and 36% for Axis II disorder
(2). In his study, he found that the lifetime prevalence of depressive disorders
alone in this population was 56%, compared with the known lifetime prevalence of
depressive disorders of about 17% in the general population. Glinski noted that
gastric bypass surgical candidates tend to use denial as a defense mechanism for
avoiding negative emotions. In keeping with this, overeating may serve as
distraction from negative emotion in these individuals. Somatization is another
tendency in this particular population.
Some improvement of psychosocial functioning after surgical treatment of
obesity has been reported (3). Van Gemert et al. recently investigated the longterm effects of surgically induced weight loss on the psychological functioning of
morbidly obese patients. They found that preoperative subjects had elevated
values on negativism, somatization, and shyness scales on personality profiles;
postoperatively, all these values normalized except somatization.
Thus,
postoperative patients still were concerned about their health and still were inclined
to react to psychological stress with physical complaints.
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Interestingly, Waters et al. found that the dramatic improvement in those mental
health indices observed 6 and 12 months after gastric bypass surgery tends to erode
to preoperative values two years after surgery, despite no weight gain (4). As a
possible explanation for this psychological regression, Waters’s group noted that
for the first 12 postoperative months, patients have frequent clinic visits that taper
off over the second year: continued psychological support may remain essential
for patients after bariatric surgery. Moreover, patients with previously diagnosed
Axis I disorders may require more support than those without. When Halmi et al.
evaluated 80 morbidly obese patients after gastric bypass, they found that those
patients with documented psychiatric diagnoses had a significantly greater amount
of psychosocial stress than those without those diagnoses (1).
Impact of Past Sexual Abuse on Obesity and Outcome after Gastric Bypass
Sexually abused women are more likely than nonabused women to receive a
psychiatric diagnosis during their lifetimes (5). Women with a history of sexual
abuse are also more likely to experience somatically based stress disorders and
somatic disorders in general (6). Moreover, multiple studies have found a
relationship between childhood sexual abuse and extreme obesity. Associations
between childhood physical abuse and obesity, as well as between childhood
neglect and obesity, also have been found (7), but core psychological reasons may
differ.
A chart review of 131 patients by Gustafson et al. revealed that 60% of those
who reported a history of sexual abuse were more than 50 pounds overweight,
compared with 28% of age-and-sex-matched patients without a history of sexual
abuse (5). In addition, 25% of the abused group was found to be more than 100
pounds overweight, compared with only 6% of controls. Researchers have
proposed that the obesity may serve as protection from sexual advances from
potential abusers. Wiederman et al. showed that among obese women, those with
a history of sexual abuse reported less body dissatisfaction and less weight
fluctuation during adulthood compared with obese women who were not sexually
abused, indicating that excess weight likely serves a particular function in sexual
abuse victims (8). Moreover, King, et al found in an outpatient weightmanagement program that research subjects with a history of sexual abuse lost
significantly less weight than those with no history of abuse (9). It has been
suggested that weight reduction in these patients may trigger anxiety symptoms as
women approach the weight at which they were abused (5, 9).
Researchers have examined the correlation between sexual abuse history and
weight-loss treatment failure. In general, childhood sexual abuse survivors are less
likely to be successful in maintaining weight loss after obesity treatment (10).
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King et al. showed that obese individuals with a history of sexual abuse were more
likely to have experienced psychological distress and to have lower self efficacy
than their counterparts who were not abused, making compliance with an obesity
treatment program exceedingly difficult in comparison. It follows that a history of
sexual abuse is an important pretreatment variable that may have a significant
impact on obesity treatment outcome (9). Although Buser et al. showed in their
study that females with a history of sexual abuse were as successful with weight
loss for the first 14 months after gastric bypass surgery as those without a history
of sexual abuse, they do validate the necessity of additional support during and
after weight loss interventions for individuals with a history of sexual abuse (11).
Psychogenic stuttering
Stuttering is generally categorized as developmental or acquired. Adult-onset
stuttering is either a reemergence of a childhood (developmental) stutter or
acquired, either neurogenic or psychogenic in nature. The mechanism of
developmental stuttering still is not well-understood: impaired neuronal
communication, disturbed timing of activation in speech-relevant brain areas, and
neuroanatomical abnormalities in the speech-language areas all have been
implicated (12, 13). Neurogenic causes of acquired stuttering include head injury,
stroke, degenerative disease of the central nervous system, brain tumor, brainsurgery, defects in the basal nuclei or thalamus, and drug-induced brain
dysfunctions (14, 15). In a case series by Roth, et al. involving 12 subjects with
adult-onset stuttering that turned out to be psychogenic in nature, all initially
required differentiation of neurologic from psychogenic stuttering through
interdisciplinary collaboration. All 12 subjects with psychogenic stuttering
presented with other, concomitant neurologic-like complaints which also turned
out to be nonorganic in etiology (16).
Psychogenic stuttering is well-described (15). The term “conversion reaction,”
which refers to a process, through which psychological stress is converted into a
somatic symptom, largely has replaced the older term “hysteria.” Psychogenic
stuttering, once known as “hysterical stuttering,” currently is considered a
conversion disorder: an alteration in physical functioning that suggests a physical
disorder but is an expression of psychological conflict (15).
The sudden onset of psychogenic stuttering is commonly preceded by an
emotionally traumatizing event. Ten of the twelve patients that comprised Roth’s
aforementioned case series had significant psychological disturbances surrounding
the onset and development of the stuttering; the remaining two subjects were
equivocal in this regard (16). Mahr and Leith recently described a woman with an
abuse history who was struggling with her decision to leave her husband when she
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suddenly began to stutter (15). Deal has suggested that adult-onset nondevelopmental and non-neurologically based stuttering usually has a sudden onset
and is temporally linked to some form of psychological trauma or cumulative
psychological stress (17). He reported an adult patient who had two discrete
episodes of sudden-onset stuttering, each after an unsuccessful suicide attempt.
Mahr and Leith have presented a clear synthesis of the most up-to-date
diagnostic schemes for psychogenic stuttering. Defining criteria 1. a change in
speech pattern suggesting stut-tering; 2. a relationship to psychological factors; 3.
absence of organic cause. Associated symptoms 1. history of mental illness; 2.
atypical features of stuttering, such as no secondary symptoms and no islands of
fluency; 3. la belle indifference. These authors have proposed that for stuttering to
be diagnosed as a conversion reaction, all defining criteria must be met in addition
to one associated symptom (15).
As opposed to developmental stuttering, for which studies have demonstrated a
1:3 female:male ratio, psychogenic stuttering has been shown to occur in a 1:1
female: male ratio (14).

CASE REPORT
Ms. S is a 44-year-old Caucasian female who, two years after Roux-en-Y gastric
bypass for morbid obesity, presented to us with a 4-month history of severe
stuttering. Neurologic symptoms were present also, which had been intermittent
over the last year but worse over the last four months. As a result of symptoms,
she had stopped working. Bipolar affective disorder had been diagnosed 15 years
earlier, and, in addition, she reported childhood sexual abuse.
Ms. S has been hospitalized several times for bipolar illness. One admission was
for feeling “low” after separation from her first husband; another was for
adjustment of her psychiatric medications. Lithium had caused a “toxic reaction,”
valproic acid gave her “decreased touch sensation,” then carbamazepine was
started without adverse effect. More recently, low dose quetiapine was also
initiated. Of note, stuttering began prior to the initiation of quetiapine. This patient
has no history of substance abuse.
Past medical history is significant for obesity, which worsened after the births of
her three children in her early twenties. Tubal ligation was carried out in her late
twenties. The gastric bypass-operation mentioned above was accompanied by open
cholecystectomy.
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Ms. S was thin as a child, but gained weight at puberty: she was afraid to be
around boys, and her developing body triggered memories of sexual abuse at age
three by her father. In her adolescence she avoided boys and tried to “hide” in her
weight. “A lot of therapy” over the years helped her deal with her childhood
sexual abuse until she reached a point where she no longer psychologically
“needed” the weight.
She has a Bachelor’s Degree, has completed graduate-level coursework, and has
been employed in the field of career-development. She married in her early
twenties and felt supported by her husband, although the intimate nature of their
relationship was limited. Her three children, with whom she has a close
relationship, are from this marriage. After 20 years of marriage, Ms. S and her first
husband divorced, owing to his involvement with other women. Following the
divorce, Ms. S proceeded with gastric bypass, which resulted in a loss of 200
pounds. Over the next year, she found herself to enjoy dating, which involved
physical intimacy with men. About one year ago, she married her current husband,
whom she describes as supportive, and with whom she is frequently physically
intimate. She does report that her new husband has told her that he likely would
not have taken interest in her had she been overweight when they first met.
Two siblings suffer from a mood disorder and from substance abuse; alcoholism
has been present in both parents. Her father died from a brain tumor, and her
grandfather had Parkinson’s disease.
She is pleasant and friendly, stuttering on many of her words. She does not
“mind the stuttering” and says with a smile that she “would not want to associate
with people who would take issue with it anyway.” She reports an active social
life and has been initiating conversation with new people without selfconsciousness. Her “flippers,” which she calls her minimal bilateral arm fat, seem
to be of more concern to her than is the stuttering. However, she does report that
stuttering and occasional double vision interfere with her ability to work because
she could not answer phones effectively or drive safely. As she describes matters,
she has become highly dependent on her husband and her children to drive her to
numerous medical appointments that now occupy much of her time.
Affect is labile during interviews; she is tearful when speaking about her bipolar
disorder and the inability of medications to “fix it.” Throughout her life, she has
felt that care providers have not believed her regarding her mood symptoms. This
has frustrated her; she compares it to times in her childhood when her mother
would not believe she was sick unless there was objective evidence, such as a
fever. The patient cites low self-esteem as her biggest lifelong psychological
problem, often feeling that she is “a bother” to people, particularly when she has
depressed mood. She worries that her new husband may leave her, and she fears
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gaining weight because “looks” are very important to him. Even so, things have
been going well in the last year: a generally supportive marriage and a rewarding,
albeit stressful, job. Ms. S has been told that her stuttering may be related to
“anxiety,” but is confused because stress level has been much higher in other times
of her life. Stuttering has never existed in the past. Moreover, she asserts, the only
person she has ever known who stuttered is a character on a television program
that she used to watch often.
She is unable to recount the details around the sudden onset of stuttering, but
recalls that it started at the end of a vacation with her husband about one month
prior to termination with her therapist of eight years; the latter was moving across
the country. Ms. S now states that were she to stop stuttering, she might “miss it,”
because it has become part of her “identity.” She does not believe that she has
received more attention since the stuttering began. She has stopped working, going
on disability and enjoying her new status as a “domestic engineer.”
Extensive neurological workup was carried out for the following complaints:
stuttering, continuous for 4 months, of sudden onset; double vision, about 20
percent of the time, for 4 months; hand tremor, at rest, for one week; and memory
and attention difficulties over the past month. Tremor was not observed during
serial physical examinations, and unsteadiness with tandem gait and difficulty with
balance were present on some occasions but not others; finger-nose-finger and
heel-to-shin exercises were within normal limits. In sum, physical findings were
inconsistent and elaborated. A thorough ophthalmic evaluation showed no
abnormalities. MRA and MRI imaging was unremarkable, and testing was
negative for infectious, endocrinologic, metabolic, and rheumatologic processes.
Speech evaluation revealed a moderate to severe dysfluency in about 50 percent
of all spoken words, persisting when reading slowly. Certain behaviors were
missing that normally accompany dysfluencies in adults: prolongations of sounds
and secondary mannerisms (increased facial muscle or laryngeal tension). Neither
discontinuation of quetiapine nor reduction in the dose of carabamazepine
improved the patient’s symptoms.
When the symptoms initially arose, Ms. S had begun to schedule more medical
and psychiatry appointments; this was shortly before termination with her therapist
of eight years. Since, she has seen psychiatrists at more than one facility and has
sought multiple primary care visits. Chief complaints vary; one such is that of
urinary symptoms (but they are unaccompanied by evidence of infection). Weekly
psychotherapy sessions were initiated at our institution, but her care soon was
transferred to a facility closer to her home.
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DISCUSSION
Neurologic complications of bariatric surgical procedures do occur, neuropathy,
encephalopathy, vitamin B12 deficiency, and thiamine deficiency, for example
(18). Although we found no evidence of an organic basis for our patient’s
symptoms, we did find from speech and psychological evaluations that, in addition
to la belle indifference, nearly every criterion (see above) of Mahr and Leith for
psychogenic stuttering was present. And multiple and vague quasi-neurologic
symptoms accompanied the complaint of stuttering, just as Roth observed in all
twelve of his psychogenic-stuttering subjects (16).
Accepting the diagnosis of a conversion reaction in this patient, what
unconscious psychological conflict does Ms. S express through her stuttering? A
number of possibilities exist. A therapist of eight years recently moved away. This
abrupt termination took place alongside the recent, steady diminution of this
patient’s medical appointments since the bariatric operation, cutting her contact
with care providers significantly. As mentioned, Waters has noted an erosion of
mental health about two years after gastric bypass surgery (4). This also is when
some patients tend to regain weight. Ms. S fears gaining weight because she
worries that her husband will leave her if she becomes obese. On the other hand, as
a sexual abuse survivor, without the protection of obesity she may be especially
vulnerable to unconscious fear (9). Somatic symptoms produce the nurturing care,
the protection, of family and healthcare workers. She can cite many instances in
her life when she has tried to communicate her needs and has not been believed;
stuttering is noticeable; it demands attention. And, given the involvement of the
oral cavity in stuttering, one might wonder if the symptom represents a
displacement of guilt or fantasy about either oral sex or eating. These would be
topics to further explore in dynamically oriented psychotherapy.
Could the emergence of Ms. S’s somatic symptoms have been prevented? A
history existed of both bipolar affective disorder and childhood sexual abuse: one
could argue that she was predisposed to psychological deterioration after her
identity-altering surgery. According to both Waters and Buser, additional and
continued psychological support should be offered to patients following bariatric
operations, particularly those with a history of a psychiatric disorder and a history
of childhood sexual abuse (4, 11).
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Psychiatric Diagnoses in Patients with
Williams Syndrome and Their Families
Janet C. Kennedy, M.D. (PGY1), David L. Kaye, M.D., Laurie S. Sadler, M.D.

ABSTRACT
Williams Syndrome (WS) is a genetic disorder associated with mental
retardation (MR) and a distinct behavioral phenotype including a friendly
and outgoing personality. This population, like others with MR, has been
reported to have an increased rate of symptoms of mental illness; however,
few studies have used DSM-IV criteria to quantify specific psychiatric
diagnoses in WS and the prevalence of psychiatric illness in relatives of
individuals with WS and the possible relationship between family and patient
diagnoses is currently unknown.
Methods: Twenty-one families participated; the patients’ average age was 16
years. DSM-IV diagnoses were applied by using the Anxiety Disorders
Interview Schedule (ADIS, Parent and Child Versions) and the Family
History Screen.
Results: A diagnosis from the ADIS was applicable to 13 patients (62%), and
in 16 patients (76%) a diagnosis was applicable in their first-degree family
members. Ten patients (48%) had some form of anxiety, specific phobia
being the most common. Three patients (14%) had major depressive disorder
and 9 patients (43%) had attention-deficit/hyperactivity disorder (ADHD).
The presence of anxiety or mood disorders in patients with WS and the
presence of these disorders in their family members were unrelated.
Conclusions: Patients with WS have a high prevalence of anxiety disorders
and of ADHD. The presence of psychiatric disorders in WS did not appear to
have a significant relationship to family history of psychiatric disorders,
consistent with the hypothesis that the specific genetic alteration in WS causes,
or contributes to causing, the anxiety disorders and the ADHD that are so
common in the disorder.
Populations with mental retardation (MR), especially those with known genetic
alterations, offer a window into the effects of genes on determining cognition and
behavior. Populations with MR are known to have increased rates of emotional
distress and mental illness (1, 2). While estimates vary, the prevalence of
Jefferson Journal of Psychiatry, Volume 20, Number 1
© 2006 by the authors
On the Web: jdc.jefferson.edu/jeffjpsychiatry

ISSN 1935-0783

22

psychiatric disorders in individuals with MR is reported as three to four times than
in the general population (3). Of children with MR living in the community, 2035% have been found to have a comorbid mental illness (2). Reported rates of
psychiatric diagnoses in this population have varied, ranging from 12% to 42% (2).
More recent studies demonstrate the prevalence of psychiatric disorders in MR
children to be 33-40% (4, 5). When DSM-IV criteria are used, 39% of a cohort of
mentally retarded children have a diagnosable mental illness (6)
Williams syndrome (WS) serves as a prototype for studying the relationship
between genetics and behavior because affected patients have a strikingly similar
behavioral phenotype. WS results from a deletion that includes the elastin gene on
chromosome 7q11.23 and occurs in 1 in 10,000-20,000 births (7, 8). Most cases
result from a new mutation. The associated mental retardation generally results in
an IQ between 41 and 80 (8). Other characteristics of WS include short stature,
specific facial features, hyperacusis, and cardiovascular defects. Individuals with
WS demonstrate relative strengths in auditory rote memory and verbal ability.
Compared to other mentally retarded individuals with similar IQ, children with WS
speak more fluently, possess larger vocabularies, and are better conversationalists
(8). Additionally, these patients are highly sociable, an affability sometimes
described as a “cocktail party personality”: talkative, overfriendly, and outgoing;
they notably lack stranger anxiety.
Individuals with WS frequently exhibit psychiatric symptoms: generalized
anxiety and worries, negative mood, and sensitivity to criticism. Behavioral and
emotional disturbances have been reported in up to 80% of children with WS,
much higher than in other mentally retarded populations (9). They have
significantly more fears as well as a wider range of frequently occurring fears as
compared to other mentally retarded populations, and also have an increased
prevalence of anticipatory anxiety (10).
Even so, few studies have used DSM-IV criteria to quantify specific psychiatric
diagnoses. Additionally, there is little research examining the possible relationship
between family history of psychiatric illness and psychiatric diagnoses in WS
patients. This study aims to identify the prevalence and nature of psychiatric
disorders in patients with WS using standard DSM-IV criteria. The study also
aims to determine the prevalence of psychiatric disorders in first-degree relatives
of WS patients and examine the possible relationship between family history of
psychiatric illness and patient symptomatology. We hypothesized that if mood,
anxiety, or ADHD disorders were a part of the WS behavioral phenotype in and of
itself, there would be no relationship between the presence of those disorders in
patients and their presence in family members.
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METHODS
All patients age 7 years or older who have been evaluated at the Williams
Syndrome Clinic of Women and Children’s Hospital of Buffalo, NY were
contacted by mail and telephone to participate in the study. The Williams
Syndrome Clinic is a multidisciplinary center that regularly evaluates patients from
a large geographic area. Patients were excluded from the study if a biological
parent was not the primary caregiver. Twenty-one of 28 eligible families agreed to
participate. All were Caucasian. All children with WS lived at home with one or
both parents. They ranged in age from 7-28 years (mean 16 years); 14 of the 21
patients were female. All patients had WS that was confirmed by fluorescence in
situ hybridization (FISH) analysis. Seven patients had currently or previously taken
one or more pharmacologic agents for treatment of psychiatric or behavioral
symptoms.
Patients and both parents, when available, were interviewed in their own
homes by a single examiner (JCK). Seventeen families (81%) had both parents
present at the time of interview. Subjects and parents received information on the
nature of the study and the assessment tools; subjects and the parents that were
present gave written informed consent. The study methods were approved by the
Institutional Review Board of Women and Children’s Hospital of Buffalo. Parent
and child responses and diagnoses were reviewed by a child and adolescent
psychiatrist (DLK).
Measurements
The Anxiety Disorders Interview Schedule (ADIS) is a standardized semistructured interview that uses DSM-IV criteria to assess for 14 psychiatric
disorders in children and adolescents, including anxiety, specific phobia, MDD,
and ADHD (11). The ADIS was administered separately to the parents and the
individual with WS (using both Parent and Child Versions) to arrive at a single
combined score. In order for a diagnosis to be assigned, symptom-criteria must be
met and must interfere with functioning. An impairment in functioning is defined
by a minimum score of 4 on a scale of 0 to 8, as rated by both the subject and the
parents in answer to the questions: “How much has [the problem] messed things up
for you with friends, in school, or at home? How much does it stop you from
doing things you would like to do?”
The Family History Screen (FHS) is a semi-structured interview assessing
lifetime history for 15 psychiatric disorders in subjects and first-degree relatives
(parents and siblings) (12). The FHS was administered separately to each
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biological parent. Diagnoses queried included anxiety, specific phobia, MDD, and
ADHD.
Data Analysis
Descriptive analyses were used for the prevalence and distribution of psychiatric
diagnoses in the study population. The association between patient and family
history of selected disorders was analyzed using Fisher’s exact tests for
contingency tables. Disorders examined in subjects and family members were
MDD, any anxiety, specific phobia, and ADHD, as these were expected to be the
most prevalent based on previous studies (1, 13). Because anxiety and depression
may occur together, analyses were also performed for any mood or anxiety
disorder. Fisher’s exact test was chosen over the Chi-square test for independence
because of the small cell- frequencies (expected cell frequencies < 5) in all of the
2x2 contingency tables. For Fisher’s exact test, the null hypotheses of
independence was performed at a 0.05 significance level. All of the statistical
analyses are performed on SAS version-9.

RESULTS
DSM-IV Diagnoses in WS population
Thirteen of 21 subjects (62%) had at least one DSM-IV diagnosis (Table 1). The
most common were: any anxiety disorder (48%), specific phobia (43%), ADHD
(43%), and generalized anxiety disorder (GAD) (24%). Major depressive disorder
(MDD) was found in 3/21 (14%) of the patients. There were no significant
differences with regard to sex or age for any diagnosis. More than one diagnosis
was present in 33% of the sample; 24% had more than 2 diagnoses.
Phobias. Specific phobia was present in 43% of patients and was the most
common type of anxiety disorder, present in 9 of the 10 subjects with an anxiety
diagnosis.
The most common types of specific phobia were animal,
thunderstorm/lightning, and loud noises. Seven of the 9 patients had multiple
phobias. No subject had social phobia.
ADHD. Of the subjects with ADHD, 8 of 9 were of the inattentive type, 1 was
the combined type, and none were of the hyperactive-impulsive subtype.
ADIS diagnosis requires a functional interference score greater than 4 out of 8.
Many more of these subjects met a symptom-criteria for diagnosis but did not meet
the requirement for functional interference. Fifteen subjects (71%) demonstrated
symptoms of specific phobia but only 9 (43%) had significant impairment in
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functioning. Two additional subjects met criteria for GAD, and 4 additional
subjects met criteria for ADHD but again did not meet the functional interference
requirement.
Table I. Diagnoses in Williams Syndrome Patients
Diagnosis

n

%

Any Diagnosis

13

62

Any Anxiety Disorder

10

48

Separation Anxiety

1

5

Social Phobia

0

0

Specific Phobia

9

43

Panic Disorder

1

5

Agoraphobia

1

5

Generalized Anxiety Disorder

5

24

Obsessive-Compulsive Disorder

0

0

Post Traumatic Stress Disorder

1

5

Dysthymia

2

10

Major Depressive Disorder

3

14

Any ADHD

9

43

ADHD-Inattentive

8

38

ADHD-Impulsive

0

0

ADHD-Combined

1

5

Conduct Disorder

0

0

Oppositional Defiant Disorder

1

5

Family History of Psychiatric Diagnoses
Seventy-six percent of subjects had first-degree relatives with any diagnosis on
the FHS. The ADIS diagnoses used in statistical analysis were: MDD, any
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anxiety, specific phobia, and ADHD. Variables examined were: presence or
absence of a diagnosis in the subject, and presence or absence of the diagnosis in
first-degree relatives.
Of the WS subjects with MDD, 2 of 3 had a first-degree family history of MDD;
of those without MDD, 6/18 had a first-degree family history of MDD. There was
no statistically significant association between family history of MDD and subject
MDD (p = 0.5308).
Of the WS subjects with any anxiety diagnosis, 4/10 had a first-degree family
history of anxiety; of subjects with no anxiety diagnosis, 6/11 had a first-degree
family history of anxiety. There was no statistically significant association between
family history of anxiety and subject anxiety (p = 0.6699).
Of the WS subjects with a mood or anxiety disorder, 6/11 had a first-degree
family history of a mood or anxiety disorder; 7/10 subjects without a mood or
anxiety disorder had a first-degree family history of a mood or anxiety disorder.
There was no statistically significant association between family history of mood
or anxiety disorders and subject mood or anxiety disorders (p = 0.6594).
No WS subject with specific phobia had a family history of specific phobia (0/9).
Two subjects out of 12 with no diagnosis of phobia had a family history of specific
phobia. There was no statistically significant association between first-degree
family history of specific phobia and subject specific phobia (p-value = 0.4857).
Of the subjects with ADHD, 2/9 had a first-degree family history of ADHD; 1/12
without ADHD had a first-degree family history of ADHD. There was no
statistically significant association between family ADHD and subject ADHD (pvalue = 0.5534).
In summary, no statistically significant association was found between family
history of MDD, any anxiety, specific phobia, and ADHD and the presence of
these disorders in WS subjects.

DISCUSSION
The WS patients of this report have a higher prevalence of psychiatric disorders
compared with other populations of MR children and adults (62% vs. 39%) (6), as
well as compared with cognitively normal children (62% vs. 12%) (14). An
increased prevalence of psychiatric diagnoses was observed even when impairment
in functioning was required for diagnosis. The rates for specific diagnoses would
have been higher if not for this requirement (e.g., 71% vs. 43% for specific
phobia). The use of impairment in functioning is a distinctive aspect of this study
and rarely has been used in previous studies.
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Anxiety was the most prevalent diagnosis in the study population: 10/21 patients
(48%). Five of these patients (24%) had GAD while 9 of 10 (43%) met diagnostic
criteria for specific phobia. Types of phobias included animals, thunderstorms,
loud noises, and high places. While some phobias may be attributed to the
hyperacusis described in WS, not all phobias were related to sound. Most patients
with phobias to loud noises also had phobias that were not sound-related. Despite
the frequent occurrence of phobias, no patient had social phobia, consistent with
the hypersociability that characterizes WS. This strong desire for social interaction
appears to be an exception to the other anxieties observed in WS patients.
Previous studies of anxiety in WS have yielded similar results. Dykens reported
excessive worry in 57% of children and adults with WS (10). However, using a
DSM-III-R parent interview, only 16% of patients met diagnostic criteria for GAD,
similar to the 24% observed in this study. Similarly, while 96% of patients
reported persistent anxiety-producing fears, only 35% met diagnostic criteria for
specific phobia (10). A multisystem study of WS adults that used the ADIS
reported anxiety disorders in 65% of patients, with specific phobia being the most
common subtype of anxiety (15). The present study further supports that anxiety
disorders, especially specific phobia, appear to be distinctive behavioral findings in
patients with WS. Of interest, despite frequent preoccupations in patients with WS,
no patient met DSM-IV criteria for obsessive-compulsive disorder.
Nine patients (43%) met criteria for ADHD, with 8 of the 9 having the
inattentive type. This is higher than rates reported in studies of other MR
populations (4-21%) (1,13). Features of inattention and distractibility have
previously been described in WS (16). Distinguishing ADHD from other features
of mental retardation is, admittedly, difficult. For example, it may be that the
hyperacusis in WS or some other attribute of MR contributes to distractibility.
Alternatively, it may be that inattention is part of the behavioral phenotype of WS.
Only three patients (14%) were found to have a history of MDD. This appears
consistent with estimates in the normal pediatric population of 8-20% (17) and in
other studies of MR children of 4-10% (1).
Previous studies have not assessed the prevalence of psychiatric disorders in
relatives of WS patients. Although psychiatric illness was common in first-degree
relatives of the patients of this study (76% with any diagnosis), comparison of
specific diagnoses between patients and relatives failed to yield a statistically
significant association for any diagnosis. The data were analyzed to detect any
relationship between the presence or absence of specific psychiatric disorders in
family members and the presence or absence of each disorder in the WS patient.
The absence of any significant relationship with family history is consistent with
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our hypothesis that the presence of psychiatric illness in WS may be caused by the
specific chromosomal deletion rather than the genetic contribution implicit in the
family history of psychiatric illness. However, the statistical analyses performed
were limited due to the small frequencies of the outcome measurements.
Extrapolation of the data from the Fisher’s exact test indicates that at least 60
subjects would be needed to find a statistically significant relationship among the
variables. Therefore, while the results are suggestive that there may be a
chromosomal link between psychiatric illness and WS, the data are insufficient to
prove this conclusion.
Additional study limitations should be mentioned. As in any clinical research, it is
important to acknowledge the possibility of non-response bias, specifically in this
study that the families who agreed to participate may have had a different
incidence of psychiatric disorders compared with those who declined.
Additionally, there is an inherent recall bias in that families may under or overreport psychiatric illness in their family members in the presence of the
interviewer. Findings could be enhanced in future studies by using a comparison
group in the study itself, such as other MR populations. This would have been
valuable because this study included the investigation of family history of
psychiatric illness as well as the use of strict DSM-IV criteria in subjects, features
not extensively investigated previously and therefore difficult to use in comparison
analysis.
An important implication of this study is that greater attention needs to be
devoted to recognizing psychiatric problems in individuals with MR, especially
those with WS. Clinicians need to recognize the increased prevalence of specific
disorders and to monitor for these illnesses as part of routine medical care,
especially GAD, specific phobia, and ADHD. The psychiatric findings in patients
with WS may provide insight into the genetic determinants of behavior and
psychiatric illness in more generalized populations; therefore, additional research
should continue to further investigate these relationships. Future research is also
needed to systematically evaluate different treatments for anxiety disorders and
ADHD in WS and other MR populations.
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No More Cuts: The Curious Fate of SelfMutilation in Its Development
Zhabiz Kazeminezhad, M.D. (PGY4), Salman Akhtar, M.D.

ABSTRACT
In this article, we present descriptions of four young women with relatively
severe personality disorders. All four were in psychodynamic psychotherapy
and all had the symptom of self-cutting. During their treatment, it became
evident that their self-cutting had undergone a transformation and a new
symptom had appeared in its place. In three, self-cutting was substituted by
behaviors that we might call “cutting equivalents” and, in the fourth, by an
enhanced self-reflective attitude and by journal-writing. We suggest that
symptom-replacement for self-cutting may be common in its developmental
course or in its course as it becomes influenced by psychotherapy, and that the
replacement is sometimes, perhaps often, salutary.

Approaching severe personality disorders psychodynamically has its pros and
cons (1-3). On the one hand, it provides a deeper and more specific understanding
of the patient, one in which his or her symptoms are seen as intricately bound with
constitutional givens, early childhood experiences, and unconscious fantasies. On
the other hand, if symptoms are end-products of a ‘trauma-fantasy-wish-defense’
sequence, any effort aimed simply at symptom-reduction is conceptually suspect
and has practical risk. Psychodynamic models of etiology compel the prediction
that removing a manifest disturbance might be undesirable, if the underlying issues
responsible for it remain unresolved. This consideration acquires greater
significance in cases of severe personality disorders (e.g., borderline, schizoid,
antisocial, paranoid), which in some instances appear nearly intractable. The best
outcome could be that a new, less toxic symptom replaces the older, more toxic
one. Of course, if the former takes sublimatory or even “pseudo-sublimatory” form
(1), the outcome can be regarded as not bad after all.
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CASE REPORTS
Case 1
Inez is a 24-year-old nursing student with a history of self-cutting that began at
age sixteen, dwindled around age eighteen, and stopped completely by age twentyone. The onset of cutting coincided with her family’s moving in with her new
step-father. Inez felt she never belonged in that house and was like an unwanted
guest. She cut herself when the feeling of being unwanted mounted and became
unbearable. The urge to cut was more frequent, but she was able to restrict the act
to once a month for fear of getting caught.
Inez was born to adolescent parents of different racial origins who were forced
into a marriage because of the pregnancy. Inez’s mother soon began an
extramarital affair with a man who would later became Inez’s stepfather; the
parents divorced when she was twelve. Inez was aware of the infidelity, for her
mother often had taken her to the house of the mother’s lover before the divorce.
She often had told Inez, from the latter’s early childhood, that Inez was unwanted
and the cause of her mother’s unhappiness. Whenever they were separated, Inez
found herself afraid that her mother would never return.
Inez began to work in a tattoo parlor at age eighteen. As an employee, she was
able to get tattoos for free and often took advantage of this perk. Although she said
that the pain of the needles bothered her, she found great pleasure in receiving the
tattoos. She discovered even more pleasure in displaying them on her body.
Interestingly, the self-cutting decreased soon after she began working in the tattoo
parlor. Within two years, she had stopped cutting herself altogether, although she
continued to obtain new tattoos regularly.
Case 2
Emily is a 23-year-old graduate student with a history of self-cutting that began
at the age of fourteen and ended at eighteen. She began cutting herself soon after
the onset of her menses, which she experienced as traumatic. Mostly she cut on her
arms and forearms, but after her cutting was discovered by her friends she began
cutting on her belly and thighs instead. Cutting relieved the tension that would
follow on an argument with her mother. During childhood and adolescence Emily
believed that her mother did not love her. Frequent, heated arguments took place,
during which Emily would tell her mother that she hated her.
Emily had been born into a working class Catholic family that had traditional
views regarding household gender-roles. Beginning at age ten, she was expected to
begin preparing dinner before her parents came home; two older brothers had no
such responsibilities. Because of this difference in treatment, she often felt that her
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mother did not love her as much as she loved her brothers. She did not want to
grow up to be a woman. Menarche was quite disturbing to her and was soon
followed by the onset of self-cutting.
The cessation of cutting at eighteen seemed related to substitution of
masturbation three times daily, a habit that continues to the present. Much like the
self-mutilation of her adolescence, Emily considers the masturbation to be a source
of tension release. During masturbation, she often fantasizes about being raped or
otherwise forced into sexual activity: it is as if the tormented soothing of cutting
had been replaced by the sadomasochistic erotic fantasy.
Case 3
June is a 29-year-old, unemployed African-American woman with a long history
of self-cutting. Cutting began at age eight soon after being sexually abused by a
friend of her parents. The sexual molestation occurred many times but
spontaneously ceased after about a year. June would cut herself immediately after
an episode of molestation because she felt she needed to, literally and physically,
feel her emotional pain: “Talking about it wasn’t intense enough.” Cutting lessened
in adolescence when she began to act out in school, skipping classes, fighting with
classmates, and having indiscriminate sexual encounters with boys. After high
school, June eventually became monogamous and stopped self-cutting. About five
years later, it started again when a male companion had become physically abusive
towards her. After leaving that relationship, the behavior again ceased. However,
since then, June finds that affectionate sexual play is not satisfactory to her.
During sex, she likes to pretend that she is being beaten or raped, a form of selfabuse that is possibly akin to cutting.
Her parents were intravenous drug abusers who lived together at the time she
was born. Soon after, the father contracted HIV and eventually passed it on to the
mother. The latter was severely verbally abusive to June. The father has since
died. Her relationship with her mother remains ambivalent. To date, whenever
mother and daughter argue, June finds that she wants to scratch herself. Blood is
not drawn, nor is that her intent.
June’s self-cutting relieved tension, as it almost always followed the mother’s
verbal abuse. It also seemed to be related to an inability to feel satiated
emotionally by verbalizing pain. Over time, she replaced cutting herself with acts
of physical aggression toward others, sexual promiscuity, and masochistic sexual
fantasies.
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Case 4
Rebecca is a highly intelligent 22-year-old African-American college student
with a record of academic excellence dating back to childhood. She also has a
history of self-cutting that began at age twelve and ended at fifteen. She recalls that
the impetus for this behavior began with reading a magazine article written about a
young woman who had had experiences much like her own and had found
emotional release through the act of self-cutting. At a younger age, Rebecca had
experienced many events that left her anxious and tense. First, she had been
sexually abused by her grandmother as a young child. Next, her parents divorced
when she was twelve. After the divorce, her father made no attempt to contact the
family again. Rebecca had been closest to her father; he had given much love,
attention, and intellectual encouragement.
She found the razor cutting across her skin particularly pleasurable. She also
enjoyed watching blood being expressed from the site of the cut. As she
discovered such pleasures, she cut herself habitually whenever she was sad,
especially if the sadness was accompanied by an urge to cry. Cutting decreased
when she began drinking alcohol, but did not stop until age fifteen. Several factors
seem responsible for its cessation. She was discovered by family members, who
shamed her for her behavior. She also began writing in a journal about her personal
experiences and mental pain. Journal writing became an increasing part of her
personal life. During these years, whenever she felt the urge to cut, she would go to
the bathroom and intently look at the collection of used and bloodied razors; this
substituted, she reported, for the literal act of self-cutting.

DISCUSSION
A symptom neither arises nor is resolved independently of other conscious and
unconscious aspects of the patient’s mind and the relation between the patient and
the therapist. With such proviso, we want to assert that all four patients presented
here demonstrate the phenomenon of symptom-replacement. Self-cutting is
replaced by receiving tattoos (Inez), sadomasochistic sexual fantasies (Emily),
fighting and provocative role-playing during sex (June), and wistfully looking at
bloodied razors (Rebecca). An explicit form of self-mutilation is thus transformed
into its “aim-inhibited” versions (4). Yet important differences in the four cases
can be discerned. Inez, the patient with the most traumatic background, replaced
self-cutting by another assault on her body, tattooing. Emily and June channeled
self-destructive propensities away from body into mental life, binding their
masochism with libido to create erotic sadomasochistic fantasies. Rebecca showed
a mixed outcome. On the one hand, masochism moved from body to mind
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(although unerotically). On the other hand, she began to write about the internal
distress that had given rise to self-cutting in the first place, showing ego growth
and an adaptation akin to sublimation.
The difference in the outcome of self-cutting in these patients is multiplydetermined (5), just the way the symptoms themselves were. Three variables
readily come to mind. First is the intensity of childhood trauma. Second is the
degree of constitutional resilience, present in one instance in the form of high
intelligence. The third is the presence of a reasonably sustained good object
relationship during childhood. Among our patients, the one most traumatized could
only advance from a naked form of violence against her body to becoming
tattooed. On the other end of the spectrum is the patient who had received much
love from her father in early childhood and also had high intelligence; she went
from cutting to merely looking at razors, also making journal entries about her
anguish that, in turn, paved the way to deeper psychotherapy. The outcomes and
predisposing factors for the other two patients belong somewhere in between these
two extremes.
Such observations suggest that symptom-replacement might be a frequent
occurrence during the course of development. If so, a number of factors seem
responsible for such an occurrence. With growth, the body changes and so do its
psychological meanings. Newer fantasies arise, ego grows, and, in the throes of
adolescence, super-ego becomes more abstract and softened (6). Greater life
experience provides trials for identifications and realignment of ideals. All this
results in changing symptomotology. Depending on the balance of libido versus
aggression in the psychic economy, a symptom can become better or worse or be
replaced by a parallel symptom.
And symptom-replacement can occur as a result of psychotherapy too, of course,
especially in resident-run clinics, where patients derive psychotherapeutic gains
largely from ego support, survival of the therapist’s containing capacities (7), and
inexact interpretations (8). Indeed, the emergence of a milder symptom in place of
a more disturbing one might even be a cause of celebration. This has technical
significance: when the emergence of a new, but less disturbing, phenomenon can
be correlated with the subsiding of a parallel, more severe symptom, the technical
approach should not center upon deconstruction-interpretation. Instead, affirmative
interventions and provision of ego support for the new compromise formation
should be the centerpiece of the therapeutic strategy (9).
Regardless of its context, whether developmental or in psychotherapy,
symptom-replacement in regards to self-mutilation appears to be a frequent and
often salutary occurrence. Keep in mind, however, the data we present here is
limited. As a result, our hypotheses and speculations must be regarded as tentative.
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First-Known Hypnopompic Hallucination
Occurring In-Hospital: Case Report
Paul Ballas, D.O. (PGY2)

ABSTRACT
Despite the high prevalence of hypnopompic hallucinations in the community,
to our knowledge there are no reports that have been published in the English
literature of these phenomenon observed by staff in the hospital setting.
Psychiatric or neurological evaluation often ensues if a patient reports
hallucinations in other circumstances, but when they are reported in
connection with sleep, further evaluation is rarely performed because such
events are common in the general populace. Our report emphasizes the
distinction between hypnopompic and hypnagogic hallucination as an ongoing
feature of life that someone is aware of, which we believe to be the case for
normal persons who have them, and a similar hallucination occurring for the
first time in someone who is unaware of it, at least unable to remember it. In
the latter instance, we suggest careful interview for symptoms of a sleep
disorder.
Hypnagogic (prior to sleep onset) and hypnopompic (upon arousal from
sleep) hallucinations are both phenomena that occur in normal people and
symptoms that are characteristic of narcolepsy (1, 2). They are a common
occurrence, experienced by almost everyone at least once and have also been
shown to be associated with the use or withdrawal from certain medications,
specifically, tricyclic antidepressants, opiates, and donepezil (3-5). Although
hypnopompic and hypnagogic hallucinations are generally considered to be normal
phenomenon, they have increased incidence in several psychiatric and neurologic
disorders (6). One study of over 14,000 subjects revealed that people with anxiety,
depression, or bipolar affective disorder have a two-fold increase in experiencing
hypnopompic or hypnagogic hallucinations at least once weekly. The same study
showed that people with adjustment disorders have a 1.5- fold increase in
experiencing these phenomenon at least once weekly (6-8). The notion that such
phenomena are normal may be part of the reason behind the wide variation in the
literature with regard to their lifetime incidence (hypnopompic 6-13%, hypnagogic
25–38%) (4, 9-11). Over 50 percent of people who experience them have no
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appreciable physical disorder, substance-abuse disorder, sleep disorder, or other
psychiatric disorder (12).

CASE REPORT
F.R. is a 41-year-old African American woman who had been admitted to the
medical service after one day of shortness of breath and two weeks of dull chest
pain, night sweats, and a non-purulent productive cough.
She had recently
completed a 3-week corticosteroid taper and a full course of azithromycin for an
upper respiratory infection.
The patient had a long history of asthma,
hypertension, and gastroesophageal reflux. She also had suffered from Grave’s
disease in the distant past; hypothyroidism developed later on but has been
corrected with thyroxin.
The patient was compliant with her outpatient
medications: levothyroxine, hydrochloro-thiazide, montelukast, Protonix,
fluticasone/salmeterol, continuous home oxygen, multivitamin, and inhaled
albuterol. She had no personal or family history of neurologic or psychiatric
disorders.
These medications were maintained, and intravenous corticosteroid was
initiated. Albuterol was given every 2 hours by nebulizer. Part of the protocol at
this hospital for someone receiving nebulizer treatments so often is that physicianreassessment must take place before each treatment. On the first night, after
approximately four hours of sleep, the patient was awakened for the second time;
she promptly sat up in bed, looked at her right arm, and yelled, “There’s blood all
over my arm!” The resident physician (one of the authors, P.B.) examined her arm
and saw only a clean IV placement. He informed the patient of this, but she looked
back at her arm and proffered it again saying “Look, can’t you see all this blood?”
Again the physician reassured her that there was nothing there, the patient sat still
and allowed herself to be evaluated. She showed no signs of a formal thought
disorder or of delusion, and she denied any hallucination apart from feeling and
seeing blood on her arm. Speech was organized normally. Neurological exam was
normal. Respiration remained labored, but after the assessment she went back to
sleep.
She was examined several other times over the next day and at no other time
during the admission did she have any other hallucinations or exhibit any signs or
symptoms of a neurologic or psychiatric disorder. When asked about the incident,
the patient had no memory of the hallucinations although she did remember being
awakened multiple times. When questioned about her sleep outside the hospital,
the patient did not know if she snored or had apneic episodes, but did report poor
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sleep quality (frequent unintentional awakenings) and excessive daytime
sleepiness. She was referred to a sleep specialist for further evaluation.

DISCUSSION
This case shows that even with no history of prior psychiatric or neurologic
disorders, patients in the hospital can have quite striking hallucinations upon
awakening. Given the high prevalence of hypnopompic hallucinations among
normal persons, it is no surprise many clinicians tend to disregard isolated
incidences such as the one described. And yet people who experience unusual
sleep-related events typically have been aware of them their entire lives. For
example, in adults who experience sleepwalking or sleep talking there is a high
prevalence of these phenomena since childhood (13).
We believe it is reasonable to do an in-depth interview specifically for sleep
disorders in every patient who experiences a hypnopompic or hypnagogic
hallucination for the first time. Sleep disorders are common, debilitating
conditions that often go undiagnosed, yet they increase the risk of substance abuse
and psychiatric disorders (9, 10, 14, 15). If the interview turns up symptoms
consistent with a sleep disorder, often a referral to a sleep specialist will be
indicated.
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Note: The Editorial Board made a special request that the author write this essay, and she
kindly agreed.

A Kind of Poem for My Friend and Me
Hilary O’Neill, M.D. (PGY4)

Physicians are taught to use technical, objective, impersonal language. Does a
person lose personhood if she’s described as “a 54-year-old African-American
presenting with increasing lethargy, frequent crying spells, hopelessness,
helplessness, plus suicidal ideation”? Or, more condensed even, “a 54 yo AAF w/
hx BAD,1.”
Coffee in my M-mug, and grief’s palpable. It’s my opinion. I don’t know about
an afterlife. Watching her die made me think of my end, too. Grief is palpable.
Nothing’s felt right off: so we’re taught. I went to work next day. What else is to
be done? Stop? I could see myself cold and callous: I’m training myself to be
professional. I’m a doctor. My friend’s dead, nonexistent. L just called: it’s true,
M’s dead.
Apologies. “Sorry for your loss.” Thanks. Shame. Of course I’ll miss her. And
your excellent care of my friend, thanks so much, Dr Z. Goodbye. A bunch of us
read Joyce aloud together in her room. Talked of our love of her company as she
went right on dying. We were opposed to it, but not to her wish, for it was her
wish. No relatives there; none had been called, none. She trusted us, her friends,
our band of eight. We followed her commands. Those things of hers I wanted, like
the Chinese tea chest; but I didn’t get it: another and better friend put in her claim.
How could she? How could she not know what it meant to me. Well… “I never
said I want that!” I wonder if M might have thought we went for the spoils before
she was cold, even. My grandmother used to say, “Would you be in my grave as
quick as you’re in my chair?” Marking territory, homo sapiens finding her way
home. I held her hand thinking it might be, just could be, the last breath: she and
me.
Can I know how another feels? Feel yourself in another’s shoes. Can’t happen, of
course, if the other isn’t feeling. My life progresses, and my attitude about you
does, too. Family trees get bigger, leaf out. I mourn all the changes, losing
childhood even as I get the college of choice.
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I’m lonely a year and a day after M died. I look around for her business card, call
the old number. Lo! Her voicemail still works; I say I miss her a lot. Voicemail for
the dead. I feel better. Therapy is messaging the dead.
I’m vague about existentialism, feels like nihilism. I used to read Jean-Paul
Sartre. Didn’t occur to me then there are times for meaning and times for
meaningless. It’s grey in the tunnel: grey at the end, too, maybe. Not winning wars
but living lives. The Oedipal phase, triangulation; Shakespeare and the web we
weave; triangles, lines, family trees, missing the forest for the trees. Me, you, me,
God, existentialism; I, my aunt, I, my grandmother (which?); mothers, fathers,
mine?
Last night I read old journals I’d kept in college, crying, crying: all this way, all
this way since then, and I still say the same things to myself. My friends, now in
memory, seem more distinct than they were then, on paper. Scary. Still, it’s my
handwriting; yes, it is. I don’t remember now each one I wrote about then. I loved.
I got angry. Ill-understood passions. Go on. Apologize later, cut and run, stay; be
happy. Combat rock, Clash; is it a jagged little pill? For music soothes the savage
beast; others it lulls to dreamland. The universals: music, dancing, celebrating,
mourning. The custom of the uncustomary. What sense is there in waking (one is
as in “I went to the wake”) the dead? I think wakes are sad and celebratory, for the
life that’s gone and the life going on. I’ve been to a couple. Not unhappy, not
happy. The meaning is not all about being happy, for which there’s neither pill nor
secret. (Only two sure things, says Poor Richard.) Our Declaration guarantees us
the pursuit not the capture of it. Nor is the meaning all sad, although sad has a big
role in the thing; maybe there’s a pill for that. Not for me, though, given my natural
gift already of it. I used to like math, thinking it had a lot of the answers: you got
them or not. Then I liked literature: a study of people in their time by someone in
it, their time, with them. I love psychiatry; I love medicine; I love the black, white,
and grey of them. Points, so many, many points, of view. Right and wrong and
happy and sad and lines and triangles and enviously or jealously and Latin and
English or Greek and English or English and English and so forth.
Once I wanted to be a veterinarian. My brother sneered, “You want to be a
doctor because it’s the most prestigious!” I cried and cried. Can’t be true. “You
don’t know anything about me! I want to help dogs and cats and hamsters.” Or was
it true? I thought then prestigious was a bad word, one I could never know and
therefore bad. Makes me laugh now. Not the word being bad but the way he said it.
Maybe he was explaining something. Maybe big brothers are not so…
People ask me if 40’s really bad. No. Twenty nine was bad, 39, too. I hope I get
to know about 49.
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Is my green like yours? My blue your blue. Yellow’s like sunshine, yellow’s the
streak on my back. Red is my fury and that flapper’s dress, I imagine. ROYGBIV
or the rainbow? Is there no word rhyming with orange? I live alone, don’t I? With
somebody or everyone else?
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Note: The Editorial Board made a special request that the author write this essay, and he
kindly agreed.

Mourning
Salman Akhtar, M.D.

The mere mention of the word “mourning” floods the mind with visions of tears
and funerals and sounds of wailing and sobbing. Images of crying men and
women, rituals of cremation, or of a body being lowered into a freshly dug grave,
and tear-soaked words of condolence are among our immediate associations to the
word. That it should be so is understandable, for loss of a loved one by death is the
most potent trigger of the emotional reaction called mourning.
Used in a broader fashion, the term “mourning” also refers to the chain of
sentiments aroused by any loss, big or small (1). This can range from the loss of
physical health to that of material wealth. Surgical amputation of a limb can stir up
a mourning reaction just as one’s car being stolen can. Less dramatic events also
have the potential of mobilizing the emotional sequence associated with mourning.
A missed appointment with an out-of-town friend, a misplaced Montblanc pen, and
an unexpectedly bad result in a college admissions test are all capable of causing
us to mourn.

MANIFESTATIONS AND VARIABLES
Such a broad conceptualization of mourning has commonalities with its narrower
usage. In either instance, mourning comprises of a set of emotions that unfold over
time when one is faced with a loss (2-4). Shock and disbelief (“But I met him just
last week and he appeared fine!”) are the immediate responses. These are soon
replaced by emotional pain and a desperate sense of longing. Depending upon the
gravity of the loss, there might be physiological disturbances accompanying this
stage. Pacing, sighing, clutching one’s chest, pulling at hair, rubbing hands, loss of
appetite, and disturbed sleep are often evident. As time passes, the turmoil seems
to settle. The lost person is talked about in exalted ways and all his or her
blemishes are glossed over; a lost object is an idealized object, mused Freud in his
seminal paper “Mourning and Melancholia” (5). A mentality of bargaining also
sets in: “Had I only done this or that, this loss might not have happened”. Fleeting
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moments of self-blame appear, although sustained feelings of guilt are not typical
of ordinary grief. More often one encounters irritability and even anger at the
occurrence of the loss in the first place. Sooner or later, this too passes. A sense of
profound aloneness and sadness now takes over. The bereaved finds himself or
herself fluctuating between heartache, pining for the departed one, dull
indifference, and the dawn of resigned acceptance of the changed life situation.
Gradually the rays of hope appear on the psychic horizon and the potential space
for a substitute begins to open up. The night, it seems, is turning into day.
Lest this description appear too schematic or stylized, let me hasten to add a few
caveats. First, grief comes in waves. It waxes and wanes. Just when recovery
seems at hand, one is hit by a fresh upsurge of sorrow. Grief is hardly a linear
process. The phases described here are useful largely for didactic purposes; human
experience is always more complex than a catalogue of symptoms. Second, no
mourning is ever complete and, by implication, no lost object of our affection is
ever totally given up. It only is moved to a different place in one’s heart. The pain
diminishes, to be sure, and emotions do not get readily mobilized. The wound turns
into a scar but the story remains.
A third caveat pertains to the fact that mourning is a process that takes its own
time; it takes, for instance, about two years to recover reasonably from the loss of a
truly loved one or from the breakup of a serious romantic relationship. The
process, like the healing of a bodily wound, cannot be rushed. However, it can be
delayed if certain complicating factors happen to be on the scene. Mourning over
death, for instance, is prolonged if the death was unexpected, occurred in violent
circumstances, was the result of suicide, and if the death left many unsettled
accounts, so to speak, between the deceased and the bereaved. Moreover, the
greater the impact upon the day-to-day reality of the bereaved, the harder it is to
resolve the grief. The sudden death of a wage-earning head of a household is thus
more difficult to mourn than the passing away of an elderly grandmother who was
long-suffering from terminal cancer.
Mourning over the death of a child is profoundly difficult, if not utterly
unfathomable. Not only is the occurrence contrary to the natural order of things
(e.g., grandparents die first, then parents, then children, and so on), it is tantamount
to a murder of dreams and hope for the future. Parents are left with the burden of
“survivor’s guilt” and find grieving to be a life-long nightmare. The pain is greater
when the offspring lost happens to be an adolescent. Having brought the child to
the threshold of adulthood and then to lose him or her is truly devastating. The fact
that parents are often at cross purposes with their teenage children further
complicates mourning such a loss.

Jefferson Journal of Psychiatry, Volume 20, Number 1
© 2006 by the authors
On the Web: jdc.jefferson.edu/jeffjpsychiatry

ISSN 1935-0783

47

COMPLICATED GRIEF
When grief does get stuck or complicated, the manifestations of ordinary
mourning get prolonged over time. The tendency to become teary, feel that the
deceased is not really dead, or both, normally experienced for a few days or weeks,
now extends over months and years. The language changes associated with the
acceptance of death (e.g., “Uncle Elvin is fond of sweets” changing into “Uncle
Elvin was fond of sweets”) get delayed and the dreams typical of early mourning
(e.g., seeing the dead person alive, rescuing him or her from a life-threatening
situation) continue long past a first few months.
More significantly, new symptoms appear. The most important among these is a
peculiar attitude about the physical possessions of the deceased. Under ordinary
circumstances, things left behind by someone dead are (unknowingly) divided into
three categories: things that are thrown away (e.g., a toothbrush, socks), things that
are given away to the poor (e.g., old clothes, shoes), and things that are kept and
passed on as family heirlooms (e.g., jewelry, diplomas, private journals, unfinished
manuscripts). Moreover, this disbursement is neither too quick nor too delayed; it
usually takes a few weeks to a few months. In complicated grief, however, one
notices a disregard for time in this context. One either gets rid of the deceased’s
things immediately (in a magical attempt at denying the significance of what has
just happened) or hangs onto them forever, finding oneself haplessly unable to
discard these items.
Another development is that things that ought to have been thrown away (e.g.,
dentures, old underwear, a glass eye, a half empty bottle of cold cream) are kept
and, strikingly, held onto in a very strange way. They can neither be used nor
thrown away. They cannot even be seen. Looking at them stirs up extremely
painful emotions of anxiety, pain, and sadness. These things no longer remain mere
physical artifacts; they become what Volkan has called “linking objects,” i.e.,
things that connect the bereaved with the deceased in unspoken and mysterious
ways (6).
In light of this, it is not surprising that the deceased’s grave becomes a nidus of
complex feelings on the part of the bereaved. In normal grief, the feelings one has
towards a loved one’s grave include tender respect and a peculiar mixture of
wistfulness and a sense of reunion. Visits to the grave occur around the anniversary
of the death, religiously dictated occasions, and when new members get added to
the family via weddings and births (7); over the course of time, the frequency of
such visits diminishes. However, when grief has become complicated, the grave
acquires greater emotional charge. One either avoids visiting the grave altogether
(and even forgetting its location) or becomes “addicted” to it, going there again
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and again. A displaced form of this is the phenomenon of “obituary addiction” (6),
whereby an individual with unresolved grief feels compelled to check out the
obituary section of the newspaper every day. Not finding the name of a loved one
who has died long ago provides an unconscious reassurance; it is almost as if that
person is still alive.
One thing this description leaves unaddressed is the cause or, to be accurate, the
causes, of a grief remaining unresolved. Certainly the depth of attachment one has
with the deceased and the external and internal jagged edges left over by his or her
departure contribute to the difficulty in mourning. What, however, goes contrary to
common sense is that unresolved aggression, if not actual hostility, towards the
deceased plays a significant role in "freezing" the process of grief. The dynamics
of this are as follows. When there are unspoken hostile and destructive affects and
fantasies directed at someone who dies, letting him or her go becomes tantamount
to “killing” him or her; this results from the condensation and telescoping of the
repressed anger with the reality-dictated necessity of the aggression implicit in
moving away from an object.

ASSESSMENT AND TRIAGE
Since, regardless of specialty, every physician comes into contact with situations
of grief and mourning, it is important to spell out some essentials of evaluating an
individual in such circumstances. First and foremost, upon hearing that someone’s
father or mother or brother or sister or son or daughter has died, the physician must
not restrict his or her attention to the medical aspects of the occurrence. Questions
must be asked about the expected versus sudden nature of the death, the
circumstances surrounding it, and the impact that this death has had upon the
bereaved’s day-to-day existence. Next, one should inquire about the funeral and
explore the degree to which the bereaved participated in it. The fate of the ashes (if
the deceased was cremated) or the location of the grave and the emotions that it
arouses (if he or she was buried) should also form a focus of gentle but firm
inquiry. The same applies to the physical possessions of the deceased. How quick
or how delayed was their disposition? What objects are in the bereaved’s
possession and what sort of feelings are attached to them? Raising such questions
would allow a glimpse into the progress or blockage of mourning processes. As
this conversation is taking place, the physician must also make a mental note of the
changes in language that occur with a deeper acceptance of someone’s death (see
above).
While known to most physicians, one simple fact can hardly be overemphasized:
normal grief does not require medical intervention. It is, by definition, a normal
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process. The attitude that all human suffering is not illness must be maintained;
some pains are integral to life. This does not mean that individuals in this state of
normal grief might not end up at a physician’s door. When this happens, curiosity
should be directed at the lack of social and familial support that has led to
“medicalizing” a normal process. Parallel to such investigation, the clinical
approach should consist of empathic remarks, imparting of information regarding
the nature of normal grief, and a relatively hands-off policy, coupled with
reassurance of availability should matters become more difficult. If, however, there
is growing evidence that the grief is becoming complicated (prolonged emotional
distress, unchanged language, difficulty disposing the deceased’s physical
possessions, and so on) then active therapeutic interventions do become necessary.

TREATMENT
The foregoing has implications for the sort of help one needs to offer to those
with unresolved mourning. Listening to their anguish must, of course, be
respectful and empathic; loss, after all, is not a pleasant affair. The therapist,
regardless of whether he or she is in the mental-health field or not, should allow
ample psychological space for the bereaved to elaborate their story. It is advisable
to not meddle too much with sharp, intellectual comments. What the suffering of
grief needs most is "witnessing" (8). Listening patiently and making occasional,
brief, and affirmative remarks which demonstrate that one understands the pain of
the patient is generally sufficient. The therapist may help the patient to talk in
greater detail and encourage the bringing in of the deceased's photographs for the
therapist and the patient to look at together. This would facilitate the emergence of
hitherto repressed memories and release pent up emotions.
Such credulous listening and affirmative stance should, however, not eclipse a
certain amount of therapeutic skepticism. In listening to someone with pathological
grief, one must keep one's "third ear" open for the verbal and nonverbal cues of a
hostile attitude in the patient towards the deceased (9). Such hints and allusions
should be gathered silently at first. In other words, the tragic motif of grief must be
allowed to run its course before one begins to point out that the patient has actually
been somewhat ambivalent about the deceased. It is only with the conscious
recognition and acceptance of negative feelings towards the dead person that the
patient can fully come to grips with his true psychic reality. This step is necessary
for the proper resolution of grief.
A less known technical ingredient of "re-grief therapy" (10, 11) is the use of
linking objects described above. The therapist not only encourages the bereaved to
talk more and more openly about his or her feelings of loss but also encourages
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him or her to bring “linking objects” to the office. Encountering them, touching
them, holding them, and reminiscing about them (and, through these, about one’s
complex feeling toward the lost person) helps thaw the frozen grief. That inanimate
objects should help revive and resolve emotional reactions about someone who
himself or herself has now become inanimate is an amazing paradox that, in the
midst of tears, can bring a smile of gratitude to our faces. Such, as they say, is life!
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Neuroleptic Malignant Syndrome, with
Attention to Its Occurrence with Atypical
Antipsychotic Medication: A Review
Sarah Guzofski, M.D. (PGY2), Ruben Peralta, M.D.

ABSTRACT
The neuroleptic malignant syndrome (NMS) is an idiopathic, life-threatening reaction to
antipsychotic medication.
NMS was traditionally attributed to potent dopamine
antagonism of typical antipsychotics, but cases of NMS have now been reported for each of
the newer antipsychotics. When NMS is caused by a newer, atypical antipsychotic the
presentation differs somewhat; fever, rigidity, and, possibly, death may be less frequent.
Diagnostic features, predisposing factors, and treatment are discussed, as is the important
matter of reinstituting antipsychotic treatment.

Neuroleptic malignant syndrome (NMS) is an idiosyncratic, life-threatening
reaction to antipsychotic medication, characterized principally by delirium, fever,
autonomic instability, and muscular rigidity (1). Most cases occur within a month
of starting the medication, two-thirds within the first week. NMS develops in 0.022.44 percent of patients who are prescribed antipsychotics (2-4); NMS may occur
even when doses are in the therapeutic range; the risk is somewhat greater with
rapid dose escalation and with parenteral administration.
Hyperthermia, delirium, autonomic instability, and extrapyramidal symptoms in
a person treated with antipsychotic medications should prompt consideration of
NMS. Classically, the extrapyramidal symptoms of NMS manifest as “lead pipe”
rigidity of the limbs; other extrapyramidal signs, such as tremor, and cogwheeling,
may be present. The muscular rigidity leads to rhabdomyolysis, which can in turn
result in renal failure. A wide range of mental status presentations are possible, but
patients are most often mute and stuporous.
Laboratory findings include
leukocytosis (most often 10-20,000, thought to be a stress response) elevated
creatine kinase (can reach 100,000), hypocalcemia (from muscle sequestration of
calcium), moderate elevations of LDH, AST and ALT, and elevated serum
osmolarity from dehydration. An EEG may show generalized slowing, consistent
with delirium (5). Symptoms generally develop over 24-72 hours and, in
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uncomplicated cases, the mean duration of symptoms is 13-15 days, longer if
caused by a depot medication (2). Serious complications are possible, including
renal failure, thromboembolism, respiratory failure from chest wall rigidity,
aspiration pneumonia, and arrhythmia (5).
DSM IV-TR criteria (6) for diagnosing NMS are in Table 1. A slightly different
set of criteria, proposed by Levenson (5), is also commonly employed (Table 2).

Table 1. DSM IV-TR Diagnostic Criteria for NMS
Severe muscle rigidity and elevated temperature associated with the use of neuroleptic
medication as well as 2 or more of the following
Diaphoresis
Dysphagia
Tremor
Incontinence
Changes in level of consciousness ranging from confusion to coma
Mutism
Tachycardia
Elevated or labile blood pressure
Leukocytosis
Laboratory evidence of muscle injury

Table 2. Levenson’s criteria for the diagnosis of NMS*
Major criteria
fever
rigidity
elevated creatine kinase (CK)
Minor criteria
tachycardia
abnormal blood pressure
altered consciousness
diaphoresis
leukocytosis
* 3 major criteria, or 2 major and 4 minor criteria, are required for diagnosis

In the differential diagnosis, infectious, metabolic and neurologic conditions
should be considered, depending on associated clinical features (Table 3). An
interesting debate has centered around the similarities and differences between
malignant catatonia and NMS. These two conditions, affecting a similar patient
population, can be so similar in their presenting features that some have argued
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that they are variants on a spectrum (7). Because NMS, malignant catatonia, and
serotonin syndrome are difficult to distinguish on symptomatic presentation alone,
medication history, behavioral prodrome, and timeline of symptom-evolution will
be critical to making a diagnosis.
Table 3. Differential Diagnosis
Diagnosis
Infectious: meningitis,
encephalitis, bacteremic sepsis
Metabolic: thyrotoxicosis,
pheochromocytoma
Neurologic: nonconvulsive
status epilepticus, postictal
state
Drug intoxications: MDMA,
cocaine, amphetamines
Serotonin syndrome

Lithium toxicity
Central anticholinergic
syndrome
Malignant hyperthermia
Malignant or lethal catatonia

Neuroleptic-induced heat
stroke

Suggestive Clinical Features, Indicated Lab Testing
Lumbar puncture. Consider blood and urine cultures
depending on overall clinical picture
Check TSH, urine catacholamines and metanephrines
EEG

Urine toxicology
Associated with gastrointestinal signs and symptoms
(hyperactive bowel sounds, diarrhea, vomiting), myoclonus,
hyperreflexia
Check lithium level. Myoclonus, hyperreflexia, tremor
Dry, flushed skin, diminished sweating, urinary retention,
dilated pupils
Exposure to halogenated anesthetics
Associated with hyperpyrexia, rigidity, akinesia. Review
behavior changes over previous weeks. May be preceded
by emotional withdrawal, anxiety, agitation, stereotypies,
posturing, waxy flexibility, mutism.
Suggestive history: warm environment, abrupt onset, no
extrapyramidal signs, may have absence of diaphoresis if
anticholinergic properties interfere with sweating.

Risk Factors
NMS is an idiosyncratic reaction and cannot be predicted, but there are some
identified risk factors. Young age, male gender, dehydration, agitation, rapid doseescalation, and intra-muscular administration increase the risk (5,8). Prior NMS
increases the risk for future episodes. There is some evidence for an association
between NMS and the following (9,10): concurrent lithium treatment, poorly
controlled extrapyramidal symptoms, patients with affective disorders, iron
deficiency, poor nutrition, environmental heat load, catatonia, and those drugs that
are more potent dopamine-2 (D2) antagonists.
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Pathogenesis
The pathogenesis of NMS is unknown. Observation that NMS occurred with D2
blocking agents lead to the hypothesis that D2 blockade in various regions of the
brain explained the presentation: D2 action in the reticular activating system could
cause changes in level of consciousness; D2 blockade in the nigrostriatal pathway
could cause rigidity; D2 blockade in the hypothalamus could account for
autonomic instability and impaired heat dissipation, thus hyperpyrexia from the
combination of hypothalamic dysfunction and muscle rigidity (9-11). This theory
is now challenged since atypical antipsychotics, with their lower D2 potency, are
reported to cause NMS.
NMS and Atypical Antipsychotics
There have been reports of NMS attributed to each of the atypical antipsychotics
and all of these medications are listed in the NMS Information Services’ Registry
(9). The rates and presenting symptoms of NMS in typical versus atypical
antipsychotics have not been directly compared (12), but some observations are
possible from available information. Of the 55 “probable” or “definite” cases of
NMS reported to the Neuroleptic Malignant Syndrome Information Service
between 1998 and 2002, 31 patients (56%) were on a typical antipsychotic; 24
patients (44%) were on an atypical antipsychotic (13). Cases of NMS have been
reported with even the least potent D2 antagonist, clozapine (2,14).
NMS owing to atypical antipsychotics has possibly a different presentation
compared with the traditional syndrome: less extreme CK and temperature
elevations and less common and milder rigidity (14,15). A 2003 review of 68
reported cases of NMS from atypical antipsychotics found that the mean peak CK
was 5958 and the mean maximum temperature was 38.8. Seventy eight percent of
patients had extrapyramidal symptoms. Twelve of the 68 required intensive care
and 3 patients died (2). This mortality rate is less than that historically reported in
NMS (11,16). Perhaps resulting from improved supportive care, mortality in NMS
is declining overall: from 76% prior to 1970 to 11% in a 1989 study, (2,11,17).
Treatment
If NMS is suspected, immediately discontinue all antipsychotic medication, as
well as other D2 blocking agents. A medical work-up should be initiated (see
above): NMS is a diagnosis of exclusion. Supportive care is the mainstay of
treatment for NMS and it should occur in a setting in which blood pressure,
cardiac rhythm, and pulse-oximetry can be continuously monitored. Autonomic
instability may manifest as hypertension, hypotension, tachycardia, or cardiac
arrhythmia. Chest wall rigidity can compromise respiration sufficiently to require
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intubation; intubation may also be indicated for severe aspiration pneumonia.
Urine alkalinization and adequate support with intravenous fluids may prevent
renal failure from myoglobinuria (18). Hyperthermia may require a cooling
blanket. Because hyperthermia in NMS is not mediated by pyrogens, antipyretic
medications are generally not helpful (1). Laryngeal dystonia, dysphagia,
respiratory distress, or delirium may preclude oral intake, so intravenous fluid and
parenteral nutrition may be needed (1). Prophylactic measures for deep venous
thrombosis and frequent repositioning will decrease the likelihood of
complications from rigidity and prolonged immobility (5). The medication list
should be reviewed: anticholinergic agents or other drugs that interfere with heat
dissipation should be discontinued (1).
Medication may hasten response to supportive therapy and decrease mortality
(19,20), but controlled clinical trials do not exist, and drug studies that are
available have not always shown benefit (21). The two most commonly used
pharmacologic interventions are bromocriptine, a central dopamine agonist, and
dantrolene, which facilitates skeletal muscle relaxation via calcium release from
the sarcoplasmic reticulum (5,9,22). Dantrolene is available in a parenteral form;
bromocriptine can only be administered orally. Symptoms of NMS sometimes
return if treatment is discontinued before complete clearance of the offending
medication, so, if bromocriptine, dantrolene, or both are utilized, treatment should
be continued for ten days beyond the resolution of symptoms, or for 2-3 weeks if
the offending agent has been an extended release depot antipsychotic (5).
Oral or intravenous benzodiazepine, the mainstay of early treatment of catatonia,
may decrease fever and rigidity in NMS, in addition to treating agitation (1).
Respiratory status should be monitored. Positive results have been reported with
diazepam (23) and lorazepam (24).
Electroconvulsive therapy (ECT) is another treatment option and may decrease
hyperpyrexia, diaphoresis, and delirium, possibly by modulating dopamine activity
in the brain. Onset of response, on average, is after 4 treatments (12). ECT should
be considered especially for patients who have not improved after 48 hours of
pharmacologic treatment, if it is not clear whether the cause of the symptoms is
neuroleptic malignant syndrome or malignant catatonia, and if the underlying
psychiatric diagnosis is a mood disorder (12,25-28).
Antipsychotic treatment after NMS
Patients with a history of NMS are likely to require future antipsychotic
treatment. The estimated risk of developing NMS again with repeat exposure to a
D2 blocker is 30%, and the risk of mortality from subsequent NMS episodes is
estimated to be as high as 20%) (13). Treatment decisions are further complicated
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by the observation that not all patients will experience a recurrence, even if they
are treated with the same drug.
There are very few formal studies documenting the outcome of antipsychotic
treatment after NMS. Several reviews of this topic were written in the late 1980s
(28-30, 32). For example, Olmstead reviewed 29 rechallenges reported in the
literature; 13 of the 29 had a recurrence, and 2 of those patients died; the most
common agent used for rechallenge was the low potency agent thioridazine (13 of
29 patients, causing 2 recurrences of NMS, one culminating in death) (29).
Rechallenges that produce recurrence of NMS are reported with a variety of
medications. Rechallenge at least 2 weeks after the initial episode appears to be
safer, and recurrence is more likely if high potency medication or high doses are
used (1). In a 1989 review, Rosebush and colleagues report that 13 of 15 patients
with prior NMS experienced no recurrence on rechallenge (30). And two small,
longer-term reviews found that in a majority of patients who are rechallenged with
antipsychotic medication NMS does not recur (31,32).
Based on these reviews, on the observed risk factors for NMS, and on theoretical
speculation about pathogenesis, we come to the following as recommendations for
reinstituting treatment after the first episode, with the understanding that the
evidence supporting them is limited. Weigh risks, benefits, and alternatives to
antipsychotic medication. If alternatives are poor and the benefit outweighs the
risk, restart antipsychotic after a 4-week waiting period following the resolution of
the episode. Begin with a low dose, advance slowly toward the target dose, and
choose an agent with low D2-nigrostriatal affinity (an atypical or a low potency
typical). Monitor carefully for fever, autonomic instability, mental status change,
extrapyramidal symptoms, and dehydration. Serial measurements of white blood
cell count and CK are warranted. Agitation should be treated aggressively with
benzodiazepine, since agitation increases the risk for NMS. Adjunctive treatment
with a mood stabilizer, antidepressant, or both for affective symptoms may
minimize, possibly, the required dose of antipsychotic (22,29,33). Velamoor has
suggested considering prophylaxis with amantadine or bromocriptine (22).
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Editorial: NMS, and Why We Should Call It
(Malignant) Catatonia
Robert Arnold Johnson, M.D. (PGY4)
The review in the current issue by Guzofski and Peralta, “Neuroleptic Malignant
Syndrome, with Attention to Its Occurrence with Atypical Antipsychotic
Medication: A Review,” reminds me of the influence of a name. I am thinking here
of the name, “neuroleptic malignant syndrome” (NMS), which was coined by
Delay in 1960, following reports of “catatonic-like” states resulting from
phenothiazines, and popularized through an influential review by Caroff in 1980
(1, 2).
A very similar syndrome, recognized as an advanced (excited, lethal, malignant,
pernicious) form of catatonia had been described well before the advent of the
typical antipsychotic medications. And catatonic features often are an overt feature
of NMS (3-5). In addition, simple catatonia is recognized as a risk factor for NMS
if typical neuroleptic is given (5). Even so, the name of NMS took on a life of its
own, a meme, we might say, that began to spread from one psychiatrist’s mind to
another independently of the meme(s) for catatonia, despite the efforts of some to
stem the tide (3). I offer as proof of this last sentence two first-hand observations.
First, I find that few of my peers are aware of a link between, or similarity of,
NMS and malignant catatonia (MC). Second, Doctors Guzofski and Peralta did not
include much mention of MC in their original submission. And, I suspect, nothing
unusual at all resides in either of these observations. A very large number of
psychiatrists and psychiatry residents do not realize NMS and MC are linked
concepts, that’s my guess. I have been luckier myself. Two of my mentors when I
was a PGY2 on the Consultation-Liaison rotation here at Jefferson, Dr. David
Lynn and Dr. Dimitri Markov, taught me about MC and encouraged me to dig into
its literature; as I did that, I learned about its link with NMC. And for that I have
most to thank Dr. Max Fink and his colleague, Dr. Michael Alan Taylor (6, 7).
They are not the only, or even the first, authors to speak of a link between MC and
NMS (3), but Dr. Fink, especially, has been the most declamatory on the topic, the
one most emphatic that the matter of language, the matter of the name, has a lot to
do with how we clinicians behave.
His point of view is that NMS is a variant of, or a subtype of, MC: MC that
happens to have been triggered by an antipsychotic medication. (The same is true,
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he believes, of serotonin syndrome: a subtype of MC, one that has been triggered
by serotonergic excess.) And this view has a highly practical implication, namely,
that treatment that is effective for catatonia should not be withheld from those
suffering from NMS. He is thinking of benzodiazepine (lorazepam is used most
often) and, should that medication prove ineffective within a few days,
electroconvulsive therapy (ECT). The dose of lorazepam that is required is often
quite high, so the schedule by which it is advanced will need to be aggressive
(taking care not to produce oversedation or respiratory compromise, of course); it
can be given parenterally, and should be in some instances (8).
So, having brought the memes of MC and NMS together in your mind, you
become vigorous in the application of benzodiazepine. But it is in the early use
(“early” in a relative sense) of ECT that your thinking is most changed by
comparison with your thinking had the two memes remained estranged. And that’s
because the NMS meme, as an isolated thing, does not lead to thinking of ECT (or
benzodiazepine) early on. It is modeled on another meme (by “meme”—maybe I
should be speaking of a whole family of them—I mean, of course, a word or
phrase or idea that appears to spread from mind to mind in the Dawkins sense, as a
selfish gene might, were it possible for a gene to spread from mind to mind), that
of malignant hyperthermia (MH), which brings forward first the idea of supportive
care, especially with regard to control of body temperature and fluid volume, and
this, of course, is a fine outcome even were MC and NMS two separate things.
And next among the weapons summoned up by the NMS meme(s) is the drug
dantrolene (a direct-acting muscle-relaxant that affects calcium flux from the
endoplasmic reticulum), also bromocriptine (a dopamine agonist to fix the
hypodopominergic state that the neuroleptic caused), amantadine (another
dopaminergic drug), or both. And uncontrolled but careful clinical studies provide
good support for the use of dantrolene and dopaminergic drugs in NMS (1, 5). It’s
not that their use is to be avoided, it’s that ECT should not be put off long if they,
as adjuncts to benzodiazepine, have not relieved the disorder within a few days.
And Dr. Fink’s point is this: ECT is likely to be put off too long if the concepts of
NMS and MC are not linked in the clinician’s mind, brought together in the one
idea that the former is a special subtype of the latter. Two excellent books on
catatonia, both published recently, support this opinion and document its history
(9, 10).
No randomized studies of ECT in MC or NMS exist, but clinical experience with
its good effectiveness in these conditions, which I, following Fink and several
others, shall link together as one, is fairly extensive (1, 2, 5, 6, 11-14). It appears to
be safe generally, but at least two patients have died as a consequence, so some
caveats are in order. First is that neuroleptic must be stopped as far in advance of
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the procedure as possible (which should have been the case at the time of diagnosis
anyway), as the two deaths mentioned were both in patients in whom neuroleptic
had been continued (15). The neuroleptic in these cases was a typical one, but the
caveat almost surely should extend to the newer, atypical antipsychotics also.
Second is that succinylcholine should be avoided as the paralyzing agent for ECT
if at all possible; this agent is known to predispose to abrupt hyperkalemia
(possibly the mechanism of death for the two cases mentioned), and conditions
favoring hyperkalemia are already extant in the situation (muscular injury from
rigidity and high body temperature; possible renal compromise from myoglobinuria and extracellular volume depletion; possibly a direct potassium-releasing
effect of ECT on skeletal muscle). The third follows from what has just been said:
serum potassium should be monitored very closely and great care should be taken
to ensure that extracellular volume has been repleted by adequate intravenous
supple-mentation (16).
Thinking of MC, NMS, and serotonin syndrome (SS) as variations on the same
theme, that of catatonia, makes it easier for me to remember how they present,
mainly as the same picture with some interesting differences: the excited,
prodromal phase may be missing and muscular rigidity earlier in NMS;
gastrointestinal distress, and maybe myoclonic seizures, more prominent in SS.
Seeing the one family makes it easier to pick up the distinctions among its
members. And, speaking of families, what a large number of conditions has been
reported to cause catatonia! Most of the reports are of the “benign” (simple,
retarded) form (BC), but I see no reason to presume that a condition capable of
causing BC could not also cause MC, as the latter may occur as an “advanced”
stage, or complication, of the former. I have gathered the conditions that I have
come across in the literature into two tables. The citations for these, in many
instances, are in the articles or books cited in the References section.

Table 1. Psychiatric Predispositions to Catatonia


mood disorders
mania or depression: ~ 50% of catatonias; 25-50% of all catatonics are manic



schizophrenia & other psychoses
~ 15% of catatonic adults; higher % in children







autism spectrum disorders
obsessive-compulsive disorder (at least the PANDAS form)
dissociative disorders/hypnosis
narcolepsy
periodic catatonia (a rare familial form, maybe autosomal dominant)
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Table 2. Medical Predispositions to Catatonia
(Approximately 25% of catatonias have no psychiatric cause)

Neurological
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•

Von Economo’s encephalitis
HIV
Chagas disease (acute)
Lyme disease
Herpes simplex
GPI (CNS syphilis)
subacute sclerosing panencephalitis
acute disseminated encephalomyelitis
seizure disorder (esp in children), incl
postictal
postmalarial syndrome, w/ psychosis
head injury, including subdural hematoma
subarachnoid hemorrhage
basilar artery thrombosis
stroke (often cardioembolic)
Sheehan’s syndrome
paraneoplastic encephalopathy
periventricular diffuse pinealoma
tumor of septum pellucidum
subthalamic tumor, w/ hydrocephalus
alcoholic/Wernicke encephalopathy
multiple sclerosis
Parkinson’s disease
progressive supranuclear palsy
dementia with Lewy bodies
familial cerebellar-pontine atrophy
hereditary spinocerebellar degeneration
tuberous sclerosis
Creutzfeldt-Jacob disease
bilateral globus pallidus lesions
frontal, parietal, or thalamic lesions
arachnoid cyst

Systemic
•
•
•
•
•
•
•
•
•
•
•
•

SLE
FUO
TTP
Wilson’s disease
liver transplantation
hepatic encephalopathy
uremia
diabetic ketoacidosis
membranous GN
hyponatremia
burns
staphylococcal infection
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•
•
•
•
•
•
•
•
•

tetanus
tuberculosis
infectious mononucleosis
typhoid fever
PANDAS
vitamin B12 deficiency
hyperparathyroidism/hypoparathyroidism
pheochromocytoma
thyrotoxicosis
acute intermittent porphyria
Addison’s disease/Cushing’s disease

•
•
•
•
•
•

MEN, 1
hereditary coproporphyria
carcinoid tumor
homocystinuria
pellagra
Tay-Sach disease (adult form)

Toxic Effect of a Medication or Substance
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•

•
•
•
•
•
•
•
•
•

•

azithromycin
ciprofloxacin
bupropion
venlafaxine
clomipramine
methylphenidate
lithium
levetiracetam
neuroleptic (NMS)
serotonergic (SS)
corticosteroid, ACTH
fluorides
baclofen
disulfiram
cyclosporine
reserpine
metoclopramide
psilocybin
PCP
MDMA (ecstasy)
opiates
mescaline
illuminating gas
alcohol
aspirin (overdose)
strychnine
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Withdrawal from a Medication
•
•
•

lorazepam, other benzodiazepine
mixed sedative
carbamazapine

•
•
•

dopaminergic drugs
anticholinergic drugs
gabapentin

Hard to shake off vertigo from simply looking at these tables. Harder still to
imagine the disorder in the clinician’s mind, were there no unifying idea like
“catatonia” to bring them together under the one roof: otherwise we would be
trying to memorize, I suppose, the neuropsychiatric features one by one that each
was reputed to have caused. And we would have no idea at all how to proceed with
therapy. As it is, we can know this: the catatonic illness that each and every one of
these disorders can, on occasion, produce is treated in exactly the same way,
varying only according to its response to initial therapy, namely, to lorazepam! Of
course, with the exception of withholding typical neuroleptic in all catatonias until
the state is relieved, and withholding any antipsychotic, typical or atypical, in the
MC variant, it doesn’t hurt to treat the specific predisposition to the catatonic state,
too, whenever that is possible. Such is the value of a name, the right name. Which
doesn’t mean the future could not bring a better one, or reveal that we’d be better
off with more than one, and which names those should be.
Just why the two names, NMS and MC, fell apart and propagated separately is
unclear, to me anyway. It seems that some of the important writers about them in
decades past, Caroff and colleagues, and Fricchione and colleagues, took distinct
care to see that separate propagation did not occur. And yet it did. (Which is why
Dr. Fink has had to come to the rescue.) Perhaps psychiatry contains such variety it
has trouble keeping its language from splitting into dialects that soon fracture its
citizenry. Perhaps our textbook editors have under-appreciated the phenomenon of
catatonia (the topic surely gets short shrift in some), owing to having succumbed to
addictive properties in the format of the DSM-IV. The latter has an unstable
placement for catatonia (6), apparently out of loyalty, conscious or not, to the
outmoded conception that catatonia is mainly a schizophrenic condition. Perhaps
NMS, flirtatious as it is with the MH meme(s), has biological cachet for those who
are made anxious by the very subject of psychiatry, which is the mind.
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